Topigen Pharmaceuticals Inc, Montreal, a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, has initiated patient dosing in clinical protocol TPI ASM8-205, a Phase 2 safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. The inhaled anti-inflammatory, RNA-targeting drug is intended for the management of moderate to severe asthma.

This study builds on prior pharmacodynamic and safety data in a 3-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe.